Secondary Logo

AAPA Members can view Full text articles for FREE. Not a Member? Join today!

Institutional members access full text with Ovid®

What is the role of cannabidiol in refractory epilepsy?

LaFleur, Kathryn M.; Nemec, Eric C. II, PharmD, MEHP, BCPS

Journal of the American Academy of PAs: March 2019 - Volume 32 - Issue 3 - p 16–18
doi: 10.1097/01.JAA.0000553393.36249.df
Pharmacology Consult

ABSTRACT The FDA recently approved the first cannabidiol oral medication to treat refractory epilepsy in patients with Dravet syndrome and Lennox-Gastaut syndrome. This article describes the safety and efficacy of cannabidiol treatment in patients with refractory epilepsy.

At the time this article was written, Kathryn M. LaFleur was a student in the PA program at Sacred Heart University in Fairfield, Conn. Eric C. Nemec II is director of research and assessment and a clinical associate professor in the PA program at Sacred Heart University. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Mary Lou Brubaker, PharmD, PA-C, department editor

Copyright © 2019 American Academy of Physician Assistants
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website